Position in INSM
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$16,201,975
-$9,921,980 QoQ
Shares Held
151,960
-4.9% QoQ
Ownership
0.070%
of shares outstanding
% of Portfolio
1.53%
of 13F equity value
Holder Rank
#134
of 663 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INSM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Rhenman & Partners Asset Management AB holds $335,352,902 across 39 Biotechnology names. INSM ranks #6 (4.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
87,440 | $21,070,416 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
27,390 | $17,078,760 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
290,500 | $16,622,410 | |
| 4 | NRIX |
Nurix Therapeutics, Inc.
|
684,250 | $16,599,905 | |
| 5 | MIRM |
Mirum Pharmaceuticals, Inc.
|
139,205 | $16,296,729 | |
| 6 | INSM |
INSMED Inc
This page
|
151,960 | $16,201,975 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
63,050 | $15,432,748 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
30,685 | $15,242,160 |
All Filings in INSM
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16,201,975 | 151,960 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $26,123,955 | 159,760 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $19,768,333 | 113,585 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $18,992,758 | 131,885 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $17,655,778 | 175,435 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $14,151,795 | 185,500 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $4,245,960 | 61,500 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $9,454,449 | 129,513 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $6,667,371 | 99,513 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||